Suppr超能文献

SCA40对人离体支气管和人多形核白细胞的作用:与咯利普兰、SKF94120和左旋克罗卡林的比较。

Effects of SCA40 on human isolated bronchus and human polymorphonuclear leukocytes: comparison with rolipram, SKF94120 and levcromakalim.

作者信息

Cortijo J, Villagrasa V, Navarrete C, Sanz C, Berto L, Michel A, Bonnet P A, Morcillo E J

机构信息

Departamento de Farmacología, Facultad de Medicine y Odontología, Universitat de València, Spain.

出版信息

Br J Pharmacol. 1996 Sep;119(1):99-106. doi: 10.1111/j.1476-5381.1996.tb15682.x.

Abstract
  1. SCA40 (0.1 nM-0.1 mM) produced concentration-dependent suppression of the spontaneous tone of human isolated bronchus (-log EC50 = 6.85 +/- 0.09; n = 10) and reached a maximal relaxation similar to that of theophylline (3 mM). The potency (-log EC50 values) of SCA40 compared to other relaxants was rolipram (7.44 +/- 0.12; n = 9) > SCA40 > or = levcromakalim (6.49 +/- 0.04; n = 6) > SKF94120 (5.87 +/- 0.10; n = 9). 2. When tested against the activity of the isoenzymes of cyclic nucleotide phosphodiesterase (PDE) isolated from human bronchus, SCA40 proved highly potent against PDE III (-log IC50 = 6.47 +/- 0.16; n = 4). It was markedly less potent against PDE IV (4.82 +/- 0.18; n = 4) and PDE V (4.32 +/- 0.11; n = 4). 3. Human polymorphonuclear leukocytes (PMNs) stimulated with N-formylmethionyl-leucyl-phenylalanine (FMLP) produced a concentration-dependent superoxide anion generation and elastase release. SCA40 (1 nM-10 microM) produced a concentration-related inhibition of FMLP (30 nM approximately EC50)-induced superoxide production (-log IC50 = 5.48 +/- 0.10; n = 6) and elastase release (-log IC50 = 5.50 +/- 0.26; n = 6). Rolipram was an effective inhibitor of superoxide generation and elastase release (-log IC50 values approximately 8) while SKF94120 and levcromakalim were scarcely effective. 4. FMLP (30 nM) and thimerosal (20 microM) induced leukotriene B4 production and elevation of intracellular calcium concentration in human PMNs. The production of leukotriene B4 was inhibited by SCA40 in a concentration-related manner (-log IC50 = 5.94 +/- 0.22; n = 6) but SCA40 was less effective against the elevation of intracellular calcium. Rolipram was an effective inhibitor of leukotriene B4 synthesis (-log IC50 approximately 7) and intracellular calcium elevation (-log IC50 approximately 6) while SKF94120 and levcromakalim were scarcely effective. 5. It is concluded that SCA40 is an effective inhibitor of the inherent tone of human isolated bronchus. The bronchodilatation produced by SCA40 appears mainly related to PDE inhibition since the potency of SCA40 as a relaxant of human isolated bronchus was found to be close to its potency as inhibitor of PDE III activity isolated from human bronchus. In addition, SCA40 exhibited inhibitory effects on human PMN function stimulated by FMLP. These effects may be related to the ability of SCA40 to inhibit PDE IV from human PMNs while the contribution of PDE V inhibition is uncertain. We found no evidence of a role for levcromakalim-sensitive plasmalemmal K+-channels in human PMNs.
摘要
  1. SCA40(0.1纳摩尔 - 0.1毫摩尔)对人离体支气管的自发张力产生浓度依赖性抑制作用(-log EC50 = 6.85 ± 0.09;n = 10),并达到与氨茶碱(3毫摩尔)相似的最大舒张程度。与其他舒张剂相比,SCA40的效价(-log EC50值)为咯利普兰(7.44 ± 0.12;n = 9)> SCA40 >或 = 左芬氟拉明(6.49 ± 0.04;n = 6)> SKF94120(5.87 ± 0.10;n = 9)。2. 当针对从人支气管分离的环核苷酸磷酸二酯酶(PDE)同工酶的活性进行测试时,SCA40被证明对PDE III具有高效力(-log IC50 = 6.47 ± 0.16;n = 4)。它对PDE IV(4.82 ± 0.18;n = 4)和PDE V(4.32 ± 0.11;n = 4)的效力明显较低。3. 用N - 甲酰甲硫氨酰 - 亮氨酰 - 苯丙氨酸(FMLP)刺激人多形核白细胞(PMN)会产生浓度依赖性的超氧阴离子生成和弹性蛋白酶释放现象。SCA40(1纳摩尔 - 10微摩尔)对FMLP(30纳摩尔,约为EC50)诱导的超氧阴离子生成产生浓度相关的抑制作用(-log IC50 = 5.48 ± 0.10;n = 6)和弹性蛋白酶释放(-log IC50 = 5.50 ± 0.26;n = 6)。咯利普兰是超氧阴离子生成和弹性蛋白酶释放的有效抑制剂(-log IC50值约为8),而SKF94120和左芬氟拉明几乎无效。4. FMLP(30纳摩尔)和硫柳汞(20微摩尔)诱导人PMN中白三烯B4的产生和细胞内钙浓度升高。白三烯B4的产生受到SCA40的浓度相关抑制(-log IC50 = 5.94 ± 0.22;n = 6),但SCA40对细胞内钙升高的作用较小。咯利普兰是白三烯B4合成(-log IC50约为7)和细胞内钙升高(-log IC50约为6)的有效抑制剂,而SKF94120和左芬氟拉明几乎无效。5. 结论是,SCA40是一种对人离体支气管固有张力有效的抑制剂。SCA40产生的支气管舒张作用似乎主要与PDE抑制有关,因为发现SCA40作为人离体支气管舒张剂的效力与其作为从人支气管分离的PDE III活性抑制剂的效力相近。此外,SCA40对FMLP刺激的人PMN功能表现出抑制作用。这些作用可能与SCA40抑制人PMN中PDE IV的能力有关,而PDE V抑制的贡献尚不确定。我们没有发现左芬氟拉明敏感的质膜钾通道在人PMN中起作用的证据。

相似文献

4
Further analysis of the mechanisms underlying the tracheal relaxant action of SCA40.
Br J Pharmacol. 1995 Jan;114(1):143-51. doi: 10.1111/j.1476-5381.1995.tb14918.x.
9
Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.
Br J Pharmacol. 1994 Oct;113(2):445-50. doi: 10.1111/j.1476-5381.1994.tb17009.x.
10
Effects of SCA40 on human bronchi and on guinea pig main bronchi in vitro. Comparison with cromakalim.
Fundam Clin Pharmacol. 1996;10(4):368-78. doi: 10.1111/j.1472-8206.1996.tb00588.x.

引用本文的文献

1
Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.
Pulm Pharmacol Ther. 2021 Feb;66:101978. doi: 10.1016/j.pupt.2020.101978. Epub 2020 Nov 28.
3
Airways disease: phenotyping heterogeneity using measures of airway inflammation.
Allergy Asthma Clin Immunol. 2007 Jun 15;3(2):60-9. doi: 10.1186/1710-1492-3-2-60.

本文引用的文献

1
Beta-adrenoceptor agonists in bronchial asthma: role of k+-channel opening in mediating their bronchodilator effects.
Clin Exp Allergy. 1993 Oct;23(10):802-11. doi: 10.1111/j.1365-2222.1993.tb00257.x.
4
Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus.
Br J Pharmacol. 1993 Feb;108(2):562-8. doi: 10.1111/j.1476-5381.1993.tb12841.x.
6
Cardiovascular effects of SCA40, a novel potassium channel opener, in rats.
Br J Pharmacol. 1993 Nov;110(3):1031-6. doi: 10.1111/j.1476-5381.1993.tb13917.x.
7
ELEASY: a program for processing experimental enzymoimmunoassay data.
J Immunol Methods. 1993 Dec 3;166(2):297-8. doi: 10.1016/0022-1759(93)90373-f.
8
Prospects for potassium channel activators in the treatment of airways obstruction.
Pulm Pharmacol. 1993 Sep;6(3):161-9. doi: 10.1006/pulp.1993.1022.
10
K+ channel openers and suppression of airway hyperreactivity.
Trends Pharmacol Sci. 1994 Dec;15(12):463-8. doi: 10.1016/0165-6147(94)90060-4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验